JERUSALEM, June 21, 2016 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced that Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT) is transferring a $6.5 million milestone payment from the previously-announced license and investment agreement between Oramed and HTIT. The payment follows Oramed’s positive top-line results […]
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
(Reuters Health) – A large weight loss, even if regained, may help overweight people with type 2 diabetes improve their blood sugar control and cholesterol and lower high blood pressure long-term, a new study suggests. Over four years, even those who regained all of a large weight loss had greater improvements in blood sugar than […]
Eli Lilly and Co’s Jardiance diabetes drug slashed the risk of progressive kidney disease in adults with type 2 diabetes in a large trial.
France’s Sanofi said two late-stage Phase III clinical trials of its LixiLan diabetes drug had met their targets, readying it for approval in the United States in August and Europe in early 2017.
To reach payer audiences, companies have to focus far less on promotional tactics and show the value of their products.
A U.S. advisory panel recommended approval of a new diabetes drug made by Sanofi SA.
A U.S. advisory panel recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combo.
Indianapolis-based Eli Lilly and Company is on a roll, announcing that between 2014 and 2023, it may launch 20 new products.
A preliminary FDA review questioned whether Sanofi’s diabetes drug lixisenatide contributed any benefit to a fixed-dose combo product the company hopes to market.
Eli Lilly has opted to not advance a diabetes drug into a Phase III clinical trial it was developing in coordination with Canada-based Transition Therapeutics Inc.